The ABCSG24 [18] trial also found that an addition of capecitabine to epirubicin and docetaxel was associated with a greater chance of achieving pCR when the cancer was estrogen receptor negative (ER−), not when the cancer was estrogen receptor positive (ER+) receiving AT-CMX. The gene discussed is ESR1; the disease is cancer.